General practice

Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care

Laurence M Mynors-Wallis, Dennis H Gath, Ann Day, Frances Baker

Abstract

Objectives To determine whether problem solving treatment combined with antidepressant medication is more effective than either treatment alone in the management of major depression in primary care. To assess the effectiveness of problem solving treatment when given by practice nurses compared with general practitioners when both have been trained in the technique. 

Design Randomised controlled trial with four treatment groups.

Setting Primary care in Oxfordshire.

Participants Patients aged 18-65 years with major depression on the research diagnostic criteria—a score of 13 or more on the 17 item Hamilton rating scale for depression and a minimum duration of illness of four weeks.

Interventions Problem solving treatment by research general practitioner or research practice nurse or antidepressant medication or a combination of problem solving treatment and antidepressant medication.

Main outcome measures Hamilton rating scale for depression, Beck depression inventory, clinical interview schedule (revised), and the modified social adjustment schedule assessed at 6, 12, and 52 weeks.

Results Patients in all groups showed a clear improvement over 12 weeks. The combination of problem solving treatment and antidepressant medication was no more effective than either treatment alone. There was no difference in outcome irrespective of who delivered the problem solving treatment.

Conclusions Problem solving treatment is an effective treatment for depressive disorders in primary care. The treatment can be delivered by suitably trained practice nurses or general practitioners. The combination of this treatment with antidepressant medication is no more effective than either treatment alone.

Introduction

Depressive disorders are common in primary care, the prevalence of both major and minor depression being 5%. Although antidepressant medication is both convenient and effective, there is considerable demand from patients for psychological treatment. Problem solving treatment has been developed in primary care as a brief (six session) structured psychological treatment that can be delivered by members of the primary healthcare team.

In primary care problem solving treatment has been shown to be effective for emotional disorders of poor prognosis and for major depression. The treatment has been shown to be effective when given by general practitioners, and community nurses can be trained in problem solving techniques.

We examined whether a combination of problem solving treatment with antidepressant medication is more effective than either treatment alone. We also studied the effectiveness of problem solving treatment given by practice nurses compared with general practitioners when both have been trained in the technique.

Methods

Patients were recruited from the lists of 24 general practitioners working in Oxfordshire between May 1994 and September 1996.

Design A randomised, controlled clinical trial was carried out to compare four treatments for major depression in primary care: problem solving treatment given by research general practitioners; problem solving treatment given by research practice nurses; antidepressant medication given by research general practitioners; and combined problem solving treatment and antidepressant medication. We chose a selective serotonin reuptake inhibitor as the antidepressant because this class of drug is widely used in primary care.

In calculating the sample size we chose the Hamilton rating scale for depression as the main outcome measure. The SD in a previous sample of patients with depressive disorder in primary care was 4.2. Assuming a clinically significant difference of 3 on the scale, we calculated that a sample size of 160 (that is, 40 per group) would result in a power of 0.90 at 5% significance based on comparisons of two groups at a time.

Selection criteria

General practitioners were asked to refer patients aged 18 to 65 years whom they judged to have a depressive
disorder that required treatment but not urgent hospital referral. Patients were assessed within 48 hours to determine whether they met the inclusion criteria: probable or definite major depression on the research diagnostic criteria; a score of 13 or above on the 17 item Hamilton rating scale for depression; and a minimum duration of illness of four weeks.

Patients were excluded if they had an additional psychiatric disorder preceding the onset of depression; were receiving concurrent treatment with antidepressant medication or a psychological treatment, or both (patients had not to have taken any antidepressant drugs for at least a month); had brain damage, learning difficulties, schizophrenia, drug dependence, recent alcohol abuse, or physical illness precluding antidepressant medication; or had a clinical state inconsistent with participation in the research protocol—for example, psychotic features or serious suicidal intent.

**Assignment**

Patients were randomised individually to receive one of the four treatments after giving informed consent to participation in the study. Allocation to treatment group was made by a research worker, separate from both the assessors and therapists, using cards in sealed envelopes. The allocation schedule was generated by using a list of random numbers. Randomisation was stratified to ensure that all treatment groups included patients with depressive disorders of equivalent severity and chronicity.

**Treatments**

Treatment was usually given in the patient’s home or local health centre. Patients in the three single treatment groups were offered six treatment sessions over 12 weeks (weeks 1, 2, 3, 5, 7, and 11). In the combined treatment group patients were offered six treatment sessions for drug treatment by the research general practitioner together with six problem solving treatment sessions by the research practice nurse. In all treatment groups one extra treatment session could be offered if the therapist thought it clinically necessary.

At the end of the 12 weeks’ treatment patients were referred back to their general practitioners. For patients on medication the general practitioners were advised that if medication had been helpful it should be continued for a further four months before cautious withdrawal was considered.

**Problem solving treatment**

Problem solving treatment was given either by one of three research general practitioners or by one of two research practice nurses. Problem solving treatment focuses on the here and now and helps patients use their own skills and resources to function better. It is explained to patients that their psychological symptoms may be linked to psychosocial problems that they are facing. If these problems can be resolved the symptoms may improve. Problem solving occurs in the following stages:

- Clarification and definition of problems
- Choice of achievable goals
- Generation of solutions
- Choice of preferred solutions
- Implementation of preferred solutions
- Evaluation.8

The first treatment session lasts one hour, with subsequent sessions lasting 30 minutes. The treatment was set out in a treatment manual and was supervised by an experienced problem solving therapist (LMM-W).

**Drug treatment**

Drug treatment was given by the research general practitioners. Patients received either fluvoxamine (initial dose 100 mg) or paroxetine (initial dose 20 mg). Fluvoxamine was initially chosen for the study but a change to paroxetine was made because of its more widespread use in primary care. Drug treatment was given according to a treatment manual based on the manual used in the National Institute of Mental Health’s collaborative research programme on treatment of depression.9 The aim of the drug treatment was to encourage patients’ compliance with medication in a supportive and encouraging framework but with avoidance of specific psychological interventions. The dose could be varied according to the patient’s clinical state. Compliance with medication was assessed by a count of returned pills.

**Combined treatment**

In the group allocated to combined treatment patients were given medication by the research general practitioner as if they were receiving medication alone. In addition, these patients saw one of the research practice nurses for the provision of problem solving treatment.

**Assessments of outcome**

Patients were assessed on four occasions: before treatment and at 6, 12, and 52 weeks. The assessments were made by one of two experienced research interviewers who were blind to the type of treatment given.

Four main outcome measures were recorded at each assessment. Two were rated by the interviewer: the clinical interview schedule (revised)—a measure of psychological symptoms developed for use in primary care7—and the Hamilton rating scale for depression—a measure of the severity of depression. Two outcome measures were rated by the patient: the Beck depression inventory—11—a measure of severity of depression—and the modified social adjustment scale—a measure of social functioning.

**Methods of analysis**

The data were analysed with spss for Windows (version 7.5). To determine the efficacy of the four treatments, analyses of variance were computed for the four main outcome measures. An intention to treat analysis was used, with the last available result carried forward as necessary.

To determine the effects of the treatments in producing clinical recovery at the end of treatment (12 weeks) we performed an intention to treat Pearson χ2 analysis of the proportion of patients who had recovered. Patients were deemed to have clinically recovered if their score on the Hamilton rating scale for depression was 7 or less; patients with scores of 8-12 were deemed partially recovered; and patients with scores of 13 or more were deemed not recovered.13
Results

The figure shows a trial profile of the patients referred to the study. Sixty patients did not meet the entry criteria (largely because the depression was not of sufficient severity). A further 30 were eligible but refused because they thought the study would not help (16), did not want medication (eight), were feeling better (three), were moving (two), or thought there were too many questions (one). This left 151 patients who met the entry criteria (144 with definite and seven with probable major depression) and agreed to randomisation. There were no significant differences in age, sex, and severity of depression between eligible patients who agreed to participate in the study and those who did not. The demographic and clinical characteristics of the treatment groups at baseline are shown in table 1.

Treatmen received

Of the 151 patients who entered the trial, 116 (77%) completed the full course of treatment. Patients receiving problem solving treatment alone had a mean number of 4.6 treatment sessions (range 1-7); patients receiving combination treatment had a mean number of 5.2 problem solving treatment sessions (range 1-7). Patients receiving medication did so for a mean number of 10.7 weeks (range 2-12). Two patients received fluvoxamine at a final dose of 150 mg and five patients at a final dose of 100 mg. Two patients received

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Problem solving (GP)</th>
<th>Problem solving (nurse)</th>
<th>Medication</th>
<th>Combination treatment</th>
<th>Total sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (range) age (years)</td>
<td>36 (20-58)</td>
<td>33 (21-46)</td>
<td>34 (19-58)</td>
<td>35 (19-62)</td>
<td>35 (19-62)</td>
</tr>
<tr>
<td>Women</td>
<td>33</td>
<td>28</td>
<td>31</td>
<td>24</td>
<td>116</td>
</tr>
<tr>
<td>Married or cohabiting</td>
<td>19 (49)</td>
<td>21 (51)</td>
<td>17 (47)</td>
<td>18 (51)</td>
<td>75 (50)</td>
</tr>
<tr>
<td>Employed/studying</td>
<td>27 (69)</td>
<td>35 (85)</td>
<td>26 (72)</td>
<td>25 (71)</td>
<td>113 (75)</td>
</tr>
<tr>
<td>Social class I, II, IIIa</td>
<td>26 (67)</td>
<td>34 (83)</td>
<td>23 (64)</td>
<td>22 (63)</td>
<td>99 (66)</td>
</tr>
<tr>
<td>Education after 16 years</td>
<td>14 (36)</td>
<td>16 (41)</td>
<td>9 (25)</td>
<td>8 (23)</td>
<td>47 (31)</td>
</tr>
<tr>
<td>White</td>
<td>32 (86)</td>
<td>39 (95)</td>
<td>32 (88)</td>
<td>34 (91)</td>
<td>143 (96)</td>
</tr>
<tr>
<td>Duration of depression v6 months</td>
<td>13 (33)</td>
<td>13 (32)</td>
<td>12 (33)</td>
<td>13 (37)</td>
<td>51 (34)</td>
</tr>
<tr>
<td>Previous episode of depression requiring treatment</td>
<td>24 (62)</td>
<td>24 (58)</td>
<td>19 (53)</td>
<td>19 (54)</td>
<td>84 (55)</td>
</tr>
<tr>
<td>Family history of depression</td>
<td>13 (33)</td>
<td>21 (51)</td>
<td>18 (50)</td>
<td>16 (46)</td>
<td>68 (45)</td>
</tr>
<tr>
<td>Saw psychiatrist before study</td>
<td>8 (16)</td>
<td>5 (12)</td>
<td>5 (14)</td>
<td>8 (23)</td>
<td>24 (16)</td>
</tr>
</tbody>
</table>
Table 2  Mean scores on four main outcome scales at baseline and 6, 12, and 52 weeks after treatment

Outcome measures (No for whom data available) | Problem solving (GP) | Problem solving (nurse) | Medication alone | Combination | P value
---|---|---|---|---|---
Hamilton rating scale for depression:
Baseline (151) | 20.5 (18.9 to 22.1) | 20.5 (19.1 to 21.9) | 20.2 (19.1 to 21.4) | 19.8 (18.5 to 21.1) | 0.90
6 weeks (139) | 12.7 (10.4 to 15.1) | 10.4 (8.1 to 12.8) | 10.7 (8.2 to 13.2) | 10.8 (8.5 to 13.1) | 0.48
12 weeks (135) | 8.5 (5.8 to 11.2) | 8.7 (6.1 to 11.3) | 6.2 (3.7 to 8.6) | 7.5 (5.2 to 9.9) | 0.47
52 weeks (113) | 5.8 (2.7 to 8.8) | 5.9 (3.4 to 8.3) | 7.2 (5.1 to 9.2) | 5.7 (3.4 to 7.9) | 0.77
Beck depression inventory:
Baseline (151) | 29.1 (26.4 to 31.8) | 30.3 (27.9 to 32.8) | 30.2 (27.7 to 32.7) | 30.0 (27.3 to 32.6) | 0.89
6 weeks (142) | 19.7 (16.2 to 23.2) | 16.1 (12.5 to 19.6) | 15.1 (10.9 to 19.3) | 16.3 (12.9 to 19.7) | 0.30
12 weeks (135) | 12.2 (8.3 to 16.2) | 13.0 (9.4 to 16.7) | 11.8 (7.8 to 15.8) | 9.3 (6.6 to 12.0) | 0.51
52 weeks (113) | 9.6 (4.6 to 14.7) | 11.5 (6.8 to 16.2) | 11.5 (6.9 to 16.2) | 8.6 (5.3 to 11.9) | 0.71
Clinical interview schedule:
Baseline (151) | 29.6 (27.4 to 31.9) | 28.6 (26.6 to 30.7) | 29.3 (27.3 to 31.2) | 29.0 (26.5 to 31.5) | 0.93
6 weeks (139) | 19.0 (15.4 to 22.7) | 16.4 (12.7 to 20.0) | 14.0 (10.1 to 17.9) | 14.0 (10.8 to 17.3) | 0.16
12 weeks (135) | 12.4 (8.1 to 16.6) | 11.9 (8.2 to 15.7) | 9.8 (6.1 to 13.5) | 9.6 (6.3 to 12.9) | 0.62
52 weeks (113) | 8.2 (3.8 to 12.5) | 8.6 (4.8 to 12.6) | 11.5 (7.3 to 16.6) | 9.7 (5.9 to 13.6) | 0.65
Social adjustment scale:
Baseline (151) | 2.2 (1.8 to 2.7) | 2.6 (2.1 to 3.1) | 2.9 (2.7 to 3.0) | 2.9 (2.7 to 3.1) | 0.17
6 weeks (139) | 2.3 (2.2 to 2.5) | 2.4 (2.2 to 2.8) | 2.3 (2.0 to 2.5) | 2.3 (2.1 to 2.5) | 0.10
12 weeks (127) | 2.1 (1.8 to 2.3) | 2.2 (2.0 to 2.4) | 2.0 (1.8 to 2.3) | 1.9 (1.7 to 2.1) | 0.38
52 weeks (105) | 1.8 (1.6 to 2.0) | 2.0 (1.8 to 2.2) | 2.1 (1.8 to 2.3) | 1.9 (1.7 to 2.1) | 0.40

Table 3  Number (%) of patients recovered at end of treatment (12 weeks) and at 52 week follow up

<table>
<thead>
<tr>
<th>Recovery</th>
<th>Problem solving (GP)</th>
<th>Problem solving (nurse)</th>
<th>Medication alone</th>
<th>Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 weeks</td>
<td>52 weeks</td>
<td>12 weeks</td>
<td>52 weeks</td>
</tr>
<tr>
<td>Recovered (Hamilton &lt;7)</td>
<td>20 (51)</td>
<td>24 (62)</td>
<td>22 (54)</td>
<td>23 (56)</td>
</tr>
<tr>
<td>Partially recovered (Hamilton 8-12)</td>
<td>5 (13)</td>
<td>6 (15)</td>
<td>6 (15)</td>
<td>8 (20)</td>
</tr>
<tr>
<td>Not recovered (Hamilton &gt;13)</td>
<td>14 (32)</td>
<td>9 (23)</td>
<td>13 (32)</td>
<td>10 (24)</td>
</tr>
</tbody>
</table>

paroxetine at a final dose of 10 mg, 46 at 20 mg, 15 at 30 mg, and one at 40 mg.

Outcome

Table 2 shows the results at baseline and at 6 weeks, 12 weeks, and 52 weeks for all patients for whom results were available on the four main outcome measures. All four groups improved during treatment. There were no significant differences between the four treatment groups at 6, 12, or 52 weeks. Table 3 shows the numbers of patients who recovered in each group at 12 and 52 weeks according to the predetermined recovery. There was no significant difference in outcome at either point.

Discussion

An important finding from this study is the lack of any significant difference between the four treatment groups. From this we drew two conclusions. Firstly, the combination of problem solving treatment and antidepressant medication is no more effective than either treatment alone. Secondly, there is no difference in outcome if the problem solving treatment is given by a suitably trained general practitioner or by a suitably trained practice nurse.

A second important finding is that patients in all groups showed a notable improvement over the 12 week treatment period. This improvement was maintained in all groups at the 52 week follow up. In the absence of a placebo group it is necessary to compare the proportion of patients recovered in this study with those in other studies. Detailed meta-analyses of the efficacy of treatments for depression in primary care were published by the depression guideline panel in the United States. In these analyses the percentage of patients with major depression who have recovered after 12 weeks of treatment are as follows: selective serotonin reuptake inhibitors 47%, behavioural therapy 55%, cognitive psychotherapy 47%, and combination therapies 53%-54%. In a previous study that evaluated the use of problem solving treatment for major depression in primary care, 27% of patients recovered in the placebo group.

This study provides follow up data at 52 weeks, which is longer than most follow up periods for depressive disorder in primary care. The follow up was naturalistic, and general practitioners were free to provide whatever treatment was appropriate for their patients. Only about two thirds of patients overall were fully recovered at a year whatever treatment had been given. These results provide evidence that depressive disorders in primary care may be of lengthy duration even with appropriate treatment.

The nurses in this study were experienced problem solving therapists who had participated in a previous study that evaluated problem solving treatment. The general practitioners received theoretical training in problem solving treatment from an experienced therapist and then treated five patients under supervision before starting the trial. It may be that the results achieved by such a research team would be better than those in routine general practice.

When should problem solving treatment be given?

The results of this study provide further evidence that problem solving treatment is effective for the treatment of depressive disorders in primary care. An important
General practice

Key messages

- Problem solving treatment is an effective treatment for depressive disorders in primary care
- Problem solving treatment can be delivered by suitably trained practice nurses as effectively as by general practitioners
- The combination of problem solving treatment and antidepressant medication is no more effective than either treatment alone
- Problem solving treatment is most likely to benefit patients who have a depressive disorder of moderate severity and who wish to participate in an active psychological treatment

We are grateful to our therapists—Julie Wiseman, Nicole Coulon, Sandra Harrison, and Khalida Quereshi—and our research interviewers—Adrienne Garrod and Alison Bond. We are particularly grateful to the general practitioners who referred patients into the study and of course the patients who took part.

Contributors: LMM-W and DHG had the original idea for the study and together with AD drew up the protocol. The study was coordinated and run by LMM-W and AD, both of whom completed the data analysis. FB assisted with the running of the study. All four authors were involved in the preparation of the paper. LMM-W is the guarantor.

Funding: Medical Research Council.

Competing interests: None declared.

1 Blacker CV, Clare AW. The prevalence and treatment of depression in general practice. *Psychopharmacology* 1995;127:51
11 Beck AT, Ward CH, Mendelson M. An inventory for measuring depression, *Arch Gen Psychiatry* 1962;1:561-71
(Accepted 11 August 1999)

Corrections and clarifications

India: looking ahead to one and a half billion people

The picture on p 995 of this article by Robert Cassen and Pravin Visaria (9 October) was taken in Nepal, not India.

This week in the BMJ

The title of the summary paragraph on the page about maternal mortality in the former East Germany by Oliver Razum and colleagues (23 October) was wrong. Rather than worsening, the reported maternal mortality in the former East Germany declined, as stated in the text of the article (pp 1104-5).

Obituaries

John David Baun (2 October, p 923) was the second president of the Royal College of Paediatrics and Child Health from 1997, not 1987.

A randomised double blind placebo controlled trial of pentoxifylline in the treatment of venous ulcers

The affiliation of one of the authors of this paper by JJ Dale and colleagues (2 October, pp 875-8) was wrong. E A Nelson should have been described as a research fellow working in the department of health studies at the University of York, York YO10 5DQ.